Fulvestrant

Name: Fulvestrant
SKU: F8147
Availability: InStock

Product ID F8147

Cas No. 129453-61-8

Purity ≥98%

Product Unit Size	Cost	Quantity		Stock

Bulk Quote

Add to Wishlist

Quicklinks

Description
Product Info
Shipping and Storage
Downloads
References

Description

Fulvestrant is an anti-endocrine compound that exhibits anticancer chemotherapeutic benefit in the treatment of estrogen receptor (ER)-positive breast cancer. Fulvestrant causes degradation of ERs and downregulates ER expression, inhibiting cell growth. Fulvestrant also upregulates expression of UDP glucoronosyltransferase 1A4 (UGT1A4) in cancer cells. Additionally, fulvestrant exhibits some anti-hyperlipidemic benefit in clinical settings, as patients receiving it as a chemotherapeutic also exhibited lower serum levels of total cholesterol and LDL.

Product Info

Cas No.	129453-61-8
Purity	≥98%
Formula	C₃₂H₄₇F₅O₃S
Formula Wt.	606.77
IUPAC Name	(7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5, 5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16, 17-decahydrocyclopenta[a]phenanthrene-3,17-diol
Solubility	Soluble in ethanol (>200 mg/mL), DMSO (>20 mg/mL). Insoluble in water. DMF 20 mg/mL, chloroform.
Appearance	White to off white powder

Shipping and Storage

Store Temp	Ambient
Ship Temp	Ambient

Downloads

MSDS	F8147 MSDS PDF
Info Sheet	F8147 Info Sheet PDF

References

Edavana VK, Penney RB, Yao-Borengasser A, et al. Fulvestrant up regulates UGT1A4 and MRPs through ERα and c-Myb pathways: a possible primary drug disposition mechanism. Springerplus. 2013 Nov 20;2:620. PMID: 24298433.

Krell J, Januszewski A, Yan K, et al. Role of fulvestrant in the management of postmenopausal breast cancer. Expert Rev Anticancer Ther. 2011 Nov;11(11):1641-52. PMID: 22050013.

Scott SM, Brown M, Come SE. Emerging data on the efficacy and safety of fulvestrant, a unique antiestrogen therapy for advanced breast cancer. Expert Opin Drug Saf. 2011 Sep;10(5):819-26. PMID: 21699443

Camerini A, Rondini M, Garrone O, et al. Fulvestrant treatment is associated with cholesterol plasma level reduction in hormone-receptor-positive metastatic breast cancer patients. Cancer Biol Ther. 2009 Aug;8(15):1450-5. PMID: 19556864.